Fay, A. P., Fizazi, K., Matsubara, N., Azad, A., Saad, F., Giorgi, U. D., Joung, J. Y., Fong, P. C., Jones, R. J., Zschaebitz, S., Oldenburg, J., Shore, N. D., Dunshee, C. J., Carles, J., Cislo, P., Healy, C., Kirker, M., Agarwal, N. (2025). Final patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations receiving initial treatment with talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in the TALAPRO-2 study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.11121